A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Summary

The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer's disease.

Timeline

Start

2022-06-02

Primary completion

2024-08-12

Completion

2024-08-12

Outcome

Outcome not reported

Stopped: “Sponsor's Decision”

Drugs

Indications